Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Dried Blood Assessment Equivalent to Drawn Blood Samples

By LabMedica International staff writers
Posted on 14 Aug 2017
A self-sampling method for therapeutic drug monitoring (TDM) of biologicals was developed that should enhance TDM implementation by patients with various autoimmune conditions.

Investigators at the Sanquin Blood Supply Foundation (Amsterdam, the Netherlands) used the rheumatoid arthritis treatment drug adalimumab to establish the feasibility of replacing drawn blood samples with dried blood spots obtained by finger prick.

Adalimumab is a TNF-inhibiting, anti-inflammatory medication. More...
It binds to tumor necrosis factor-alpha (TNFalpha), which normally binds to TNFalpha receptors, leading to the inflammatory response of autoimmune diseases. By binding to TNFalpha, adalimumab reduces this inflammatory response. Because TNFalpha is also part of the immune system, which protects the body from infection, treatment with adalimumab may increase the risk of infections. For this reason the U.S. Food and Drug Administration issued a black box warning to doctors, which appears in the product labeling of adalimumab and other TNF-inhibiting drugs, instructing them to screen and monitor potential patients more carefully.

The investigators compared adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger pricks with measurements in serum obtained via venipuncture, from 161 patients with rheumatic inflammatory diseases. Adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively.

Results revealed that adalimumab and ADA concentrations obtained by the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient greater than 0.87). Interestingly, antibody concentrations (adalimumab, ADA, or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Experiments on spiked blood samples demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick versus venipuncture. Therefore, the investigators established a correction factor of approximately 1.2 to relate finger prick/DBS values to serum values.

"Easy home sampling at different time points will benefit patients and could help to prescribe biologics optimally," said senior author Dr. Karien Bloem, post-doctoral researcher in immunopathology at Sanquin Blood Supply Foundation.

The study was published in the August 9, 2017, online edition of the British Journal of Clinical Pharmacology.

Related Links:
Sanquin Blood Supply Foundation


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.